Hydroxychloroquine Use in Autoimmune Disease and Why UV Light Is Not a Treatment for Infection

Hydroxychloroquine is a prescription antimalarial drug also widely used in rheumatology and select dermatologic conditions. The medication’s primary clinical relevance stems from its immunomodulatory effects rather than any direct ability to “cure” infections. In credible practice, hydroxychloroquine is used for autoimmune diseases such as rheumatoid arthritis and lupus (systemic lupus erythematosus, cutaneous lupus), where modulation of aberrant immune signaling can reduce inflammation and disease activity.

Mechanistically, hydroxychloroquine accumulates in acidic intracellular compartments, including endosomes and lysosomes. By increasing the pH within these organelles, it interferes with antigen processing and presentation. This reduces activation of toll-like receptor pathways—particularly TLR7 and TLR9—that drive type I interferon production. In lupus, excess interferon signaling is linked to flares, organ involvement, and autoantibody-related pathology. Additionally, hydroxychloroquine affects cytokine production, autoantibody synthesis, and lymphocyte function, contributing to improved symptom control and reduced flares over time. Unlike antibiotics or antiviral agents, its therapeutic benefit in autoimmune conditions typically requires weeks to months.

Hydroxychloroquine dosing and patient selection are critical. Standard use for rheumatoid arthritis and lupus is weight-based and guided by established regimens, with attention to renal function because drug clearance depends partly on kidney function. Concomitant medications and comorbidities should be reviewed to minimize adverse effects and interactions. Clinicians also assess baseline risk for ocular toxicity, since hydroxychloroquine can cause retinal damage.

The most important safety issue is hydroxychloroquine-associated retinopathy, which can lead to irreversible vision loss if not detected early. Risk increases with higher cumulative doses, longer duration, concomitant renal impairment, and concurrent use of certain other medications. Patients should undergo baseline ophthalmic evaluation and periodic screening with modern retinal imaging modalities (e.g., spectral-domain optical coherence tomography and automated visual fields) based on risk stratification. Adherence to screening schedules is essential because early retinopathy may be asymptomatic.

Cardiac toxicity is another concern. Hydroxychloroquine can prolong the QT interval, which may predispose susceptible individuals to arrhythmias. This risk is heightened in those with pre-existing QT prolongation, electrolyte abnormalities (e.g., hypokalemia), or concurrent QT-prolonging drugs. Therefore, clinicians may perform baseline electrocardiography and monitor for symptoms such as syncope, palpitations, or dizziness.

Other adverse effects include gastrointestinal upset, headaches, skin hyperpigmentation, and, less commonly, neuromuscular or hematologic abnormalities. Severe toxicity is rare but can occur with overdosing, emphasizing the necessity of prescription-only use and adherence to monitoring.

The claim that hydroxychloroquine and UV light can “cure” a disease reflects a misunderstanding of evidence-based therapeutics. Ultraviolet (UV) light has legitimate applications in medicine—most notably ultraviolet phototherapy for certain dermatologic conditions such as psoriasis and some forms of eczema—where controlled dosing can influence inflammatory pathways in skin cells. However, UV light is not a general cure for systemic infections, and unsupervised UV exposure can cause burns, exacerbate skin cancers risk, and worsen photo-sensitive conditions.

For infectious diseases, treatment decisions rely on rigorous clinical trial evidence. Hydroxychloroquine’s role in viral infections has been extensively studied, and results have not supported its use as a reliable universal cure. Clinical guidelines typically discourage off-label use for unproven indications due to the balance of modest or absent benefit against meaningful risks, particularly retinal and cardiac harms.

When patients encounter misinformation that frames medication and light exposure as curative, the most constructive approach is to re-center on diagnosis, mechanism-appropriate therapy, and safety. If symptoms suggest an autoimmune flare, clinicians may use hydroxychloroquine as part of a long-term regimen rather than a rapid fix. If symptoms suggest infection, evaluation should focus on confirming the cause and selecting treatments with established efficacy, such as targeted antivirals or antibiotics when indicated.

Patients should not self-initiate hydroxychloroquine or UV exposure. Instead, they should consult qualified clinicians for individualized assessment, including baseline eye and cardiac risk evaluation when hydroxychloroquine is considered. Evidence-based care improves outcomes by aligning interventions with disease mechanisms and by reducing preventable harms. Source: @Happykittyoffla